NCT07222202 Evaluation of Flexible Conductive Hearing Aids
| NCT ID | NCT07222202 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Conductive Hearing Loss |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-01-14 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-01-14 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Conductive hearing loss (CHL) is the most common type of hearing loss among the pediatric population. CHL occurs when sound is not properly transmitted from the external ear to the cochlea, and congenital pathologies like microtia/anotia, atresia, and absent or malformed ossicles make hearing loss permanent.
Eligibility Criteria
Inclusion Criteria: * Male and female infants, children, adolescents, and adult patients who are diagnosed with unilateral or bilateral mixed or conductive hearing loss * Male and female patients seen at Atrium Health-Audiology for a clinical, standard of care office visit who have a diagnosis of conductive or mixed hearing loss and may currently wear hearing aids * Male and female infants, children, adolescents, and adults who are candidates for conductive hearing aids (Osseo-integrated or wearable aids) or for canalplasty or ossicular chain reconstruction surgery * Healthy subjects will include male and female infants, children, adolescents, and adults who do not have conductive or mixed hearing loss * Pregnant women -are eligible for this study. Standard of Care allows pregnant patients to be fit for hearing aids without risk. Exclusion Criteria: * Adult patients unable to independently understand the purpose of the study and the procedures and/or who are not willing to participate
Contact & Investigator
Mohammad Moghimi, PhD
PRINCIPAL INVESTIGATOR
Wake Forest University Health Sciences
Frequently Asked Questions
Who can join the NCT07222202 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 80 Years, studying Conductive Hearing Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07222202 currently recruiting?
Yes, NCT07222202 is actively recruiting participants. Contact the research team at Seyyed.moghimi@wfusm.edu for enrollment information.
Where is the NCT07222202 trial being conducted?
This trial is being conducted at Winston-Salem, United States.
Who is sponsoring the NCT07222202 clinical trial?
NCT07222202 is sponsored by Wake Forest University Health Sciences. The principal investigator is Mohammad Moghimi, PhD at Wake Forest University Health Sciences. The trial plans to enroll 200 participants.